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1) Hussein G, Nakagawa I円 GotoH吋 Matsumotok吋 SankawaU., Watanabe H.: Astaxanthin 
Ameliorates Features of Metabolic Syndrome in SHR/NDmcr-cp. Life Sci. 80(6): 522・529;
2007. 
Abstract: Glucose and lipid metabolic parameters play crucial roles in metabolic syndrome and its major 
feature of insulin resistance. This study was designed to investigate whether dietary astaxanthin oil 
(ASX-0) has potential effects on metabolic syndrome features in an SH＆刊Dmcr-cp( cp/cp) rat model. 
Oral administration of ASX (50 mg/kg/day) for 22 weeks induced a significant reduction in arterial blood 
pressure in SHRcp. It also significantly reduced the fasting blood glucose levelラhomeostasisindex of 
insulin resistance (HOMA-IR), and improved insulin sensitivity. The results also showed an improved 
adiponectin levelラasignificant increase in high-density lipoprotein cholesterolラasignificant decrease in 
plasma levels of triglyceridesラ andnon-esterified fatty acids. Additionallyラ ASXshowed significant 
effects on the white adipose tissue by decreasing the size of the fat cels. These results suggest that ASX 
ameliorates insulin resistance by mechanisms involving the increase of glucose uptakeラandby modulating 
the level of circulating lipid metabolites and adiponectin. 
2) Zhao Q吋 Mm
formula, ameliorates chronic cerebral hypoperfusion-induced deficits in object recognition 
behaviors and in central cholinergic systems in mice. J. Pharmacol. Sci. 103(4): 360-373; 
2007. 
Abstract: We previously demonstrated that the Kampo formula chotosan (CTS) ameliorated spatial 
cognitive impairment via central cholinergic systems in a chronic cerebral hypoperfusion (P2VO) mouse 
model. In this study, the object discrimination tasks were used to determine if the ameliorative effects of 
CTS on P2VO-induced cognitive deficits are a characteristic pharmacological profile of this formulaラwith
the aim of clarifying the mechanisms by which CTS enhances central cholinergic function in P2VO mice. 
The cholinesterase inhibitor tacrine (THA) and Kampo formula saikokeishito (SKT) were used as 
controls. P2VO impaired object discrimination performance in the object recognition, location, and 
context tests. Daily administration of CTS (750 mg/kg, p・o.)and THA (2.5 mg/kg, i.p.) improved the 
object discrimination deficitsラwhereasSKT (750 mg/kg, p.o.) did not. In ex vivo assays, tacrine but not 
CTS or SKT inhibited cortical cholinesterase activity. P2VO reduced the mRNA expression of m3 and m5 
muscarinic receptors and choline acetyltransferase but not that of other muscarinic receptor subtypes in 
the cerebral cortex. Daily administration of CTS and THA but not SKT reversed these expression 
changes. These results suggest that CTS and THA improve P2VO-induced cognitive impairment by 
normalizing the deficit of central cholinergic systems and that the beneficial effect on P2VO-induced 
cognitive deficits is a distinctive pharmacological characteristic of CTS. 
3) Li S, Wang C, Wang M, Li W, Matsumoto K, Tang Y.: Antidepressant like effects ofpiperine 
in chronic mild stress treated mice and its possible mechanisms. Life Sci. 80(15): 1373-1381; 
2007. 
Abstract: In this study, we investigated the antidepressant-like effect of piperine in mice exposed to 
chronic mild stress (CMS) procedure. Repeated administration of piperine for 14 days at the doses of2.5ラ
5 and 10 mg/kg reversed the CMS・ 
and open field activity. Furthermoreラthedecreased proliferation of hippocampal progenitor cells was 
ameliorated and the level of brain-derived neurotrophic factor (BDNF) in hippocampus of CMS stressed 
mice was up-regulated by piperine treatment in the same time course. In addition, 
3-(4ラ5-dimethylthiazol・2-yl)-2,5四diphenyltetrazoliumbromide (MTT) and lactic dehydrogenase (LDH) 
assays showed that piperine (6.25-25 μM) or fluoxetine (FLU, 1 μM) dose-dependently protected primary 
???
cultured hippocampal neurons from the lesion induced by 10 μM corticosterone (CORT). Reverse 
transcription-polymerase chain reaction (RT-PCR) was used to detect the messenger ribonucleic acid 
(mRNA) level of BDNF in cultured neurons. Treatment with piperine (6.25-25 μM) for 72 h reversed the 
CORT-induced reduction of BDNF mRNA expression in cultured hippocampal neurons. In summarγラ
up-regulation of the progenitor cel proliferation of hippocampus and cytoprotective activity might be 
mechanisms involved in the antidepressant-like effect of piperine, which may be closely related to the 
elevation of hippocampal BDNF level. 
4) Sumanont Y., Mm 
: Effects of manganese complexes of curcumin and diacetylcurcumin on kainic acid-induced 
neurotoxic responses in the rat hippocampus. Biol. Pharm. Bull. 30(9):1732・1739;2007. 
Abstract: This study aimed to investigate the mechanism underlying the protective effects of manganese 
complexes of curcumin (Cp Mn) and diacetylcurcumin (DiAc-Cp-Mn) on kainic acid (KA)-induced 
excitotoxicity in the rat hippocampus. Systemic injection of KA (10 mg/kg, i.p.) caused seizures and 
increased the expression of neurotoxic markersラ immediateearly genes [ cゾun,cyclooxygenase 2 
(COX-2), brain-derived neurotrophic factor (BDNF), and heat shock protein 70 (hsp70)] and a delayed 
response gene [inducible nitric oxide synthase (iNOS)], which were measured at 6 and 72 h after KA 
injection, respectivelyラinthe hippocampus. Pretreatment with Cp-Mn (50 mg/kgラi.p.)and DiAc-Cp Mn 
(50 mg/kgヲi.p.)but not with curcumin (50 mg/kgラi.p.)delayed the onset of KA-induced seizure without 
affecting the seizure sco民 KAinjection induced c-Fos immunoreactivity in DGラ CAlラ andCA3 
hippocampal regionsヲtheexpression of which peaked at 6 h after injection. Cp-Mn and DiAc-Cp-Mn 
treatment significantly decreased c-Fos expression elicited by KA. MoreoverラCpMn and DiAc-Cp-Mn 
administration suppressed the KA-induced expression of cゾun,COX-2, BDNFラ andiNOS mRNA, 
whereas curcumin attenuated only iNOS mRNA expression. No compounds tested had an effect on 
KA-induced hsp70 expression. It is therefore likely that in addition to radical scavenging and SOD-like 
activitiesラthesuppression of potential neuronal injury marker expression by Cp-Mn and DiAc-Cp-Mnラ
contributes to the neuroprotective activities of these compoundsラwhichare superior to those of curcumin, 
on KA-induced excitotoxicity in the hippocampus. These results suggest the beneficial effects of Cp-Mn, 
and DiAc-Cp-Mn on the treatment of excitotoxicity-induced neurodegenerative diseases. 
5) Obi R円 TohdaM., Zhao Q, Obi N., Hori H., Murakami Y吋 GotoH円 ShimadaY円 OchiaiH刊
Matsumoto K.: Chotosan enhances Macrophage colony-stimulating factor mRNA 
expression in the ischemic rat brain and C6Bu-1 glioma cels. Biol. Pharm. Bull. 30(12): 
2250-2256; 2007. 
Abstract: Macrophage colony stimulating factor (M-CSF) is a cytokine which has been recently reported 
to have a neuroprotective effect on ischemic rat brain. In this study, we investigated the effect of chotosan, 
an oriental medicine, which has been clinically demonstrated to be effective for the treatment of vascular 
dementia, on MCSF gene expression in rats with permanent occlusion of bilateral common carotid arteries 
(P2VO) in vivo and in a C6Bu-l glioma cel line in vitro. The expression level of M-CSF mRNA in the 
cerebral cortices of P2VO rats was significantly higher than that in the cerebral cortices of sham-operated 
animals. Repeated treatment of P2VO rats with chotosan (75 mg/kg per day) for 4 d after P2VO 
significantly increased the expression level of MCSF mRNA in the cortex but it had no effect on the 
expression of ~－actinラ granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony 
stimulating factor (GM-CSF) mRNAs. Moreover, the present in vitro studies revealed that chotosan 
treatment (10-100 μg/ml) ofC6Bu-l glioma cells dose”dependently enhanced MCSF mRNA expression 
without affecting the expression of G-CSF, GM-CSF, and inducible nitric oxide synthase mRNAs. The 
effect of chotosan was reversed by Ro 31-8220 ( 1 μM), a selective protein kinase C (PKC) inhibitor, but 
not by H-89 (10 μM), a selective protein kinase A (PKA) inhibitor. These findings suggest that the 
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upregulatory effect of chotosan on M-CSF mRNA expression involves PKC and may play an important 
role in the anti vascular dementia action of this formula. 
6) Chung M吋 NakamuraN., Tohda M吋 Hattori九'I.:Effects of Tokishakuyakusan on 
hypothalamic pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP type 
I receptor (PACl) expression in hypophysectomized and ovariectomized rats. J. Trad. Med. 
24: 24-30; 2007. 
7) Chung M., Tohda M. Hattori M.: Effects of Tokishakuyakusan on the ovary in 
hypophysectomized rats. J. Trad. Med. 24: 31-38, 2007. 
く〉総説
1) Matsumoto K., Puia G., Dong E., Pinna G.: GABAA receptor neurotransmission dysfunction in a 
mouse model of social isolation-induced stress: possible insights into a non-serotonergic 
mechanism of action ofSSRis in mood and anxiety disorders. Stress 10(1):3-12; 2007. 
2) 松本欣三：東洋医学と生命科学の融合を目指して脳血管性認知症病態モデ、ルにおける和
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short variantの経目的発現量変化と RNAeditingとの関連性．第58回日本薬理学会北部会，
2007, 9/29，札幌．








1) Matsumoto K.ラZhaoQ., Murakami Y.ラTohdaM., Obi R., Shimada Y.: Neuropharmacological 
evidence for availability of a Kampo medicine Chotosan in clinical treatment of vascular dementia: 
From behavior to molecular aspect. Joint Symposium: Evidence-based Approach to Traditional 
Medicine and Modem Medicine, 2007, 6126, Beijing 
2) Matsumoto K., Zhao Q.: Neuropharmacological evidence for availability of a Kampo medicine 
Chotosan in clinical treatment of vascular dementia. The 33rd Congress on Science and 
Technology of Thailand, 2007, 10/18-20, Nakhon Si Thammarat (Thailand). 
3) 松本欣三，越埼，村上孝寿，東田道久，小尾龍右，嶋田豊：脳血管性認知症治療におけ
る漢方薬・釣藤散の有用性：その実験薬理学的証拠と作用機序．第7回日本臨床中医薬学
会学術大会 日中シンポジウム I 基礎系，2007,12/8，東京．
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1) Matsumoto K.: Chotosan, a “traditional Chinese Japanese (Kampo) medicine”，may be a “modem 
promising drug" for vascular dementia treatment: Evidence from neuropharmacological studies. 














1) Erminio Costa, Alessandro Guidotti：米国イリノイ州立大学シカゴ校精神医学研究所，「ス
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トレス病態における神経活性ステロイドの役割」ラ 1997,4-
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